Ocugen (OCGN)
Develops modifier gene therapies for inherited and degenerative blindness diseases.
Something off on this page? Send us feedback.
Clinical-stage ophthalmology company developing modifier gene therapies for blindness diseases. Lead programs target retinitis pigmentosa, Stargardt disease, and geographic atrophy caused by dry age-related macular degeneration.
Develops modifier gene therapies for blindness diseases. The lead pipeline includes OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease, and OCU410 for geographic atrophy secondary to dry age-related macular degeneration. OCU400 and OCU410ST have completed enrollment for late-stage registration studies, while OCU410 remains in clinical development.
Clinical development rather than commercial product sales defines the business: the company had not generated significant revenue and has funded operations through common-stock and warrant sales, convertible notes and debt, and grant proceeds. Personnel are located in the United States, India, and elsewhere. Commercialization depends on completing clinical development and obtaining regulatory authorization.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $100.1M · Total debt $88.0M · Total assets $124.2M · Shareholders' equity −$16.6M
- Revenue
- $1.5M
- Operating income
- −$16.4M
- Net income
- −$24.9M
No dividends on record.
| Institutions | ≈ 43.10% | 146.14M shares | |
|---|---|---|---|
| 159 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.65% | 5.61M shares | |
| 6 holders · as of Sep 11, 2026 | |||
| Strategic holders | 5.90% | 20.00M shares | |
| 1 holder · as of Dec 8, 2025 | |||
| Other | ≈ 49.35% | 167.36M shares | |
| remainder | |||
339.11M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 7.96% | 27.00M | as of Jun 30, 2026 |
State Street CorpInstitution | 6.33% | 21.47M | as of Jun 30, 2026 |
Janus Henderson Group PLCStrategic | 5.90% | 20.00M | filed Dec 8, 2025 |
Vanguard Capital Management LLCInstitution | 4.24% | 14.37M | as of Jun 30, 2026 |
Millennium Management LLCInstitution | 4.11% | 13.94M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 9, 2026 | Shankar Musunuri | director, officer: Chief Executive Officer | −525,991 | $1.12 |
| Jun 15, 2026 | Treerita Essalima Johnson-Greene | officer: Chief Financial Officer | +21,000 | $1.23 |
- Biogen
Approved C3 complement therapy for geographic atrophy
- MeiraGTx
Late-stage X-linked retinitis-pigmentosa gene therapy
- Kiora Pharmaceuticals
Mutation-agnostic retinal-disease vision-restoration program
- 4D Molecular Therapeutics
Ocular gene-therapy platform with a geographic-atrophy candidate
- REGENXBIO
Late-stage AAV retinal program for wet AMD and diabetic retinopathy
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Ocugen | $1.05 | +1.94% | $349.3M | — | — | 76.3 | +8.4% |
| Biogen | $224.36 | +2.42% | $32.37B | 38.8 | 16.9 | 3.3 | +3.4% |
| MeiraGTx | $12.53 | −4.20% | $1.21B | 18.4 | — | 3.0 | +8,608.6% |
| Kiora Pharmaceuticals | $2.68 | 0.00% | $11.9M | — | — | — | — |
| 4D Molecular Therapeutics | $16.14 | +5.91% | $796.7M | — | — | 8.7 | +25,106.7% |
| REGENXBIO | $8.15 | +3.48% | $407.4M | — | — | 2.3 | +405.7% |
| Median | 28.6 | 16.9 | 3.2 | +4,507.2% |